1.80 on the TAI. This SniperIQ fundamentals page covers Taiyen Biotech's valuation (P/E 16.1x, P/B 0.9x), profitability (net margin 12.1%), revenue (NT.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$6.4B
P/E (TTM)16.1x
Net Margin12.1%
Revenue (FY25)NT
.3B

Full research coverage

Frequently Asked Questions

What is Taiyen Biotech's market cap?

Taiyen Biotech (1737) has a market capitalization of approximately NT$6.4B, trading at NT

1.80 on the TAI. Market cap moves with the live share price.

What is Taiyen Biotech's P/E ratio?

Taiyen Biotech's trailing twelve-month P/E ratio is 16.1x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.

How profitable is Taiyen Biotech?

Taiyen Biotech runs a net profit margin of 12.1%, a gross margin of 40.4%, and an operating margin of 15.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Taiyen Biotech generate?

Taiyen Biotech reported revenue of NT

.3B for fiscal year 2025, with net income of NT$400M and earnings per share (EPS) of 2. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Taiyen Biotech pay a dividend?

Taiyen Biotech offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Taiyen Biotech financially healthy?

Taiyen Biotech carries a debt-to-equity ratio of 0.03x and a current ratio of 3.25x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Taiyen Biotech a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Taiyen Biotech (1737) the key facts are: market cap NT$6.4B, P/E 16.1x, revenue NT

.3B, 52-week range 30.8-33.45. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.

Track Taiyen Biotech's full fundamentals live

Get Taiyen Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.